CEO: Paul J Heaney, PhD. Paul has a strong track record in Life Sciences & Healthcare for company leadership, fundraising, corporate development, R&D innovation and commercialisation of pioneering technologies. Commercial experience gained at executive level in both multi-nationals (GE & Kodak Clinical) and in five US & UK start-ups including two (Orchid and Sequenom) that had successful IPO’s on Nasdaq. Paul has led development and launch of a wide range of leading-edge and commercially successful clinical and research products
CSO: Prof Ivan Roitt FRS. Co-founder and co-inventor of NALIA technology. He is head of Cancer Research Institute at Middlesex University and previously Head of Departments of Immunology & Rheumatology Research at University College London. Prof. Rovit has 280 publications to his name, and is a pioneer in the research of autoimmune diseases.
Chairman: Graham Hine. Graham acted as lead investor for NALIA’s recent oversubscribed fundraising through Syndicate Room. He is a highly successful technology entrepreneur with a track record in leading, growing and successfully exiting technology companies through both trade sale and flotation. He began his career with Philips and has subsequently gained over 20 years’ CEO and Chairman experience, at companies including Capteur Sensors, P2i, Hardide and SGX Sensortech. Graham is currently Chairman of several technology companies.
Non-executive Director: Berwyn Clarke, PhD. Dr Clarke has been working in the pharmaceutical and diagnostics industries for over 25 years. His experience includes both global business such as GlaxoWellcome and Bayer Diagnostics, and small start-up companies.
Non-executive director: Ian Armitage. Ian is a highly experienced patent attorney, having worked at Mewburn Ellis for over 40 years, as well as in the pharmaceutical and biotechnology industry sectors. He has considerable expertise in EPO opposition and appeal proceedings with a reputation for successfully tackling complex legal problems in genetic engineering and biotechnology opposition/appeal cases. Ian has known NALIA for some time and was a major investor in the recent funding round.
Non Executive Director: Nigel Davis, PhD, MBA. Dr Davis has been commercialising technology for more than 24 years, with experience in biotech management and business development. His previous positions include Glaxo, Innovir, ISIS Innovation and PharmaVentures and NED at Ploughshare Innovations
Principal Scientist: Yuliya Yatsenko, PhD, has several years of experience with NALIA technology and the design and testing of multiplex immunoassay biomarker arrays.
Company Co-founder: Prof Ian Cree. Ian is a World renowned pathologist, recently appointed as Head of WHO Tumour Classification and senior pathologist at the International Agency for Research on Cancer in Lyon, France. He sits on numerous clinical and diagnostic committees and is an expert in the clinical adoption of new IVD tests